Wall Street Zen Upgrades BeOne Medicines (NASDAQ:ONC) to Strong-Buy

Posted by Francis Steltz on Jul 20th, 2026

BeOne Medicines (NASDAQ:ONC – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday.

Several other research analysts have also commented on ONC. Wolfe Research started coverage on shares of BeOne Medicines in a report on Friday, March 27th. They issued an “outperform” rating and a $340.00 price target on the stock. Barclays cut their target price on shares of BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 14th. Royal Bank Of Canada upped their price target on BeOne Medicines from $436.00 to $451.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Citizens Jmp reissued a “market outperform” rating and set a $396.00 price target on shares of BeOne Medicines in a research report on Wednesday, July 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $390.92.

Read Our Latest Analysis on BeOne Medicines

BeOne Medicines Stock Performance

NASDAQ:ONC opened at $312.02 on Friday. The firm’s fifty day simple moving average is $290.21 and its 200-day simple moving average is $308.94. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The stock has a market cap of $34.23 billion, a PE ratio of 69.80 and a beta of 0.49. BeOne Medicines has a fifty-two week low of $253.95 and a fifty-two week high of $385.22.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The firm had revenue of $1.51 billion for the quarter. Analysts expect that BeOne Medicines will post 5.86 earnings per share for the current fiscal year.

Insider Activity at BeOne Medicines

In other BeOne Medicines news, CEO John Oyler sold 145,861 shares of the company’s stock in a transaction that occurred on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the completion of the sale, the chief executive officer owned 8,122 shares of the company’s stock, valued at $2,484,925.90. This represents a 94.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Xiaobin Wu sold 1,292 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $276.26, for a total transaction of $356,927.92. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 233,647 shares of company stock worth $70,335,553. 6.19% of the stock is owned by company insiders.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its position in BeOne Medicines by 100.6% during the 4th quarter. BNP Paribas Financial Markets now owns 193,951 shares of the company’s stock worth $58,924,000 after acquiring an additional 97,244 shares during the last quarter. Capital International Sarl boosted its stake in shares of BeOne Medicines by 2.7% in the 4th quarter. Capital International Sarl now owns 152,515 shares of the company’s stock valued at $46,336,000 after purchasing an additional 3,956 shares during the last quarter. Slow Capital Inc. grew its holdings in BeOne Medicines by 51.5% during the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company’s stock worth $8,294,000 after acquiring an additional 9,280 shares during the period. Capital International Investors grew its stake in shares of BeOne Medicines by 1.3% during the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock worth $1,553,909,000 after purchasing an additional 67,808 shares during the period. Finally, UBS Group AG lifted its stake in BeOne Medicines by 45.0% in the fourth quarter. UBS Group AG now owns 152,087 shares of the company’s stock valued at $46,206,000 after buying an additional 47,172 shares during the period. 48.55% of the stock is currently owned by institutional investors.

About BeOne Medicines

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.